Mice Model

Global Mice Model Market to Reach US$2.6 Billion by 2030

The global market for Mice Model estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. CRISPR / CAS9, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$976.7 Million by the end of the analysis period. Growth in the Microinjection segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$508.8 Million While China is Forecast to Grow at 8.1% CAGR

The Mice Model market in the U.S. is estimated at US$508.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$603.1 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Mice Model Market - Key Trends & Drivers Summarized

What Are Mice Models, and Why Are They Crucial in Biomedical Research?
Mice models are laboratory mice used by scientists to study human diseases, genetics, and drug responses. These models are essential for biomedical research because mice share many physiological and genetic similarities with humans, making them excellent subjects for studying a wide range of human conditions, including cancer, heart disease, diabetes, and neurological disorders. The ability to manipulate the mouse genome and create genetically modified mice has significantly enhanced the value of these models in research, allowing for targeted studies on specific genes or disease processes. This capability makes mice models indispensable tools for understanding disease mechanisms, identifying potential therapeutic targets, and evaluating new drugs and treatments.

How Are Genetic Modifications Advancing Mice Model Research?
Genetic modifications in mice models have revolutionized biomedical research, allowing for more precise and targeted studies. Techniques such as CRISPR/Cas9 gene editing have made it possible to create mice with specific genes knocked out or modified, which can mimic human genetic conditions or diseases closely. These advancements have not only accelerated the pace of research but also improved the relevance of mice models to human health. As these techniques become more refined, they enhance the ability to model complex human diseases in mice, leading to more effective drugs, faster development timelines, and ultimately, better patient outcomes.

What Challenges Do Researchers Face With Mice Models?
Despite their extensive use, researchers face challenges with mice models, particularly concerning the accuracy with which these models replicate human diseases. Differences in mouse and human immune systems, metabolism, and biology can lead to discrepancies in how diseases manifest and respond to treatments in mice versus humans. Additionally, the high costs associated with developing, maintaining, and housing genetically engineered mice can be prohibitive, especially in high-throughput studies or in institutions with limited funding. Ethical considerations also play a significant role, as the welfare of animals in research must be meticulously managed to adhere to ethical standards and regulatory guidelines.

What Drives the Growth in the Mice Model Market?
The growth in the mice model market is driven by several factors, including the ongoing need for effective models in the rapidly expanding fields of genetics and personalized medicine. Innovations in genetic engineering and genome editing technologies have broadened the applications of mice models in research, making them more valuable for studying complex genetic interactions and diseases. The rise in chronic diseases globally and the push for more personalized, targeted therapies have also spurred demand for specialized mice models. Furthermore, the increasing investment in pharmaceutical R&D, coupled with growing collaborations between academic institutions and biotechnology companies, supports the continuous development and refinement of mice models. As the biomedical landscape evolves with new scientific advancements and regulatory requirements, the reliance on mice models is expected to remain strong, driving further innovations and expansions in this vital market.

SCOPE OF STUDY:

The report analyzes the Mice Model market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer, Other Technologies); Service (Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing, Other Services); Therapeutic Area (Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular, Other Therapeutic Areas)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

• Charles River Laboratories International, Inc.
• Envigo, Inc.
• Genoway S.A.
• Harbour Antibodies BV
• Horizon Discovery Group PLC
• inGenious Targeting Laboratory, Inc.
• Janvier Labs
• Laboratory Corporation of America Holdings (LabCorp)
• Taconic Biosciences, Inc.
• The Jackson Laboratory
• Trans Genic, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.